In my opinion, to enjoy the continued growth that global life science companies have seen over the recent decades, they must increasingly look to emerging markets as sources of development. I have noticed significant interest in the BRIC regions in recent times and certainly when I have found myself talking to candidates about their new career moves for 2014, I find the most exciting and desirable roles are no longer found in the traditional EMEA regions.
The term BRIC has been used from the turn of the 21st century and refers to Brazil, Russia, India and China. From what I have seen, establishing a growth strategy for life science companies in these regions should involve taking a detailed look at these markets individually, to find shared aims that will ensure growth whilst remaining sensitive to attributes within each specific region. I believe this cultural analysis is what makes roles in these regions more desirable to some people than their European equivalents.
The latest territories on everyone’s lips (no pun intended) are the MINT regions (Mexico, Indonesia, Nigeria and Turkey). I firmly believe that these also have an opportunity to become major players in the world economy and global companies should look at these territories for significant growth potential. In my opinion, both the BRIC and MINT regions present a diverse range of opportunities with some countries being in more mature stages than others. I would certainly suggest that the future and potential of global life science companies development and investment will need to extend far beyond traditional paths.
– Dan Haggett, Resourcing Coordinator